Pacific Biosciences Of California, Inc.PACB

NasdaqHealthcareLaboratory Analytical Instruments
Price (close)
$1.58
Market cap
$491.1M
P/E
—
Revenue (TTM)
$159.3M
Net income
-$131.4M
Dividend yield
—
1-year total return
29.5%
Net margin
-82.5%
Revenue growth
2.0%
Debt / equity
—

What Pacific Biosciences Of California, Inc. does.

We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.

Our products and technology, which include our HiFi long-read sequencing technology, address a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.

Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$78.9M$130.5M$128.3M$200.5M$154.0M$160.0M
Net income$29.4M-$181.2M-$314.2M-$306.7M-$309.9M-$546.4M
Free cash flow$18.5M-$117.1M-$280.0M-$268.0M-$212.2M-$113.9M

More on PACB.

Figures from Pacific Biosciences Of California, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.